ABCL-1224: Updated Results From EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Category Primary study
ConferenceSociety of Hematologic Oncology Thirteenth Annual Meeting
Year 2025
This article has no abstract
Epistemonikos ID: 9f01f299c7a35bec9017dd436553f60fecc1f727
First added on: Aug 30, 2025